[Clinical aspects and chemotherapy of adenocarcinoma of the kidney].
The classic triad of hematuria, pain and presence of a palpable flank mass is found only in few patients with renal carcinoma. Hematuria, the main symptom, occurs in nearly the half of patients. Blood levels of erythropoetin and renin are often elevated and may be of value as biochemical tumor markers. Chemotherapeutic agents do not alter the course of metastatic renal carcinoma significantly. Vinblastine is the most effective available drug currently. Progestins or androgens cause tumor regression very seldom. If antioestrogens or immuntherapeutic regimens may improve therapeutic results, is not to be decided at present.
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D011374:Progesterone / Q000627:therapeutic use; D045165:Testosterone Congeners / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D045165:Testosterone Congeners; D011374:Progesterone; D014747:Vinblastine
Klinik und Chemotherapie des Adenokarzinoms der Niere.